Drug Recall
Top vascular medicine news of 2019: Colchicine benefit, valsartan recall and more
In this list, Healio and Cardiology Today present the most-popular vascular medicine articles published in 2019.
ED visits spike, prescribing patterns change in wake of valsartan recall
PHILADELPHIA — When multiple generic valsartan products were recalled worldwide in July 2018 due to the presence of a carcinogenic contaminant, valsartan dispensing immediately decreased. However, there was an immediate spike in ED visits for hypertension and incomplete replacement with alternative products in some patients, according to new data presented at the American Heart Association Scientific Sessions.
FDA warns Torrent Pharmaceuticals over losartan manufacturing violations
The FDA announced it issued a warning letter to Torrent Pharmaceuticals over violations of good manufacturing practice regulations observed during an inspection of a plant producing losartan in India.
Top news of September: Losartan recalls, dapagliflozin in HF and more
Healio and Cardiology Today compiled a list of the most-viewed cardiology posts in September. This month, our readers were interested in recalls of losartan due to impurities, the DAPA-HF and DEFINE-HF studies showing benefit of dapagliflozin (Farxiga, AstraZeneca) in patients with HF regardless of diabetes status, the effect of a salt substitution regimen on hypertension and much more.